Mebhydrolin napadisylate | CAS# 6153-33-9 | antihistamine

MedKoo Cat#: 413668 | Name: Mebhydrolin napadisylate

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Mebhydrolin napadisylate is an antihistamine.

Chemical Structure

Mebhydrolin napadisylate

CAS#6153-33-9 (napadisylate)

Theoretical Analysis

MedKoo Cat#: 413668

Name: Mebhydrolin napadisylate

CAS#: 6153-33-9 (napadisylate)

Chemical Formula: C48H48N4O6S2

Exact Mass: 840.3015

Molecular Weight: 841.05

Elemental Analysis: C, 68.55; H, 5.75; N, 6.66; O, 11.41; S, 7.62

Price and Availability

Size	Price	Availability	Quantity
5g	USD 350.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

6153-33-9 (napadisylate) 524-81-2 (free base)

Synonym

Mebhydrolin napadisylate; Incidal; Omeril; Mebhydroline 1,5-naphthalenedisulfonate salt

IUPAC/Chemical Name

1,5-Naphthalenedisulfonic acid, compd. with 2,3,4,5-tetrahydro-2-methyl-5-(phenylmethyl)-1H-pyrido(4,3-b)indole (1:2)

InChi Key

CJUOSBUQOWKEKJ-UHFFFAOYSA-N

InChi Code

InChI=1S/2C19H20N2.C10H8O6S2/c2*1-20-12-11-19-17(14-20)16-9-5-6-10-18(16)21(19)13-15-7-3-2-4-8-15;11-17(12,13)9-5-1-3-7-8(9)4-2-6-10(7)18(14,15)16/h2*2-10H,11-14H2,1H3;1-6H,(H,11,12,13)(H,14,15,16)

SMILES Code

O=S(C1=C2C=CC=C(S(=O)(O)=O)C2=CC=C1)(O)=O.CN(C3)CCC(N4CC5=CC=CC=C5)=C3C6=C4C=CC=C6.CN(C7)CCC(N8CC9=CC=CC=C9)=C7C%10=C8C=CC=C%10

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

To be determined

Shelf Life

>2 years if stored properly

Drug Formulation

To be determined

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

Mebhydrolin napadisylate is a specific histamine H1 receptor antagonist.

In vitro activity:

Here this study screened FDA-approved antihistamine drugs to obtain anti-ZIKV candidate compounds and identified mebhydrolin napadisylate (MHL) that exhibits the potent inhibition of ZIKV infection in various cell lines in a histamine H1 receptor-independent manner. Mechanistic studies suggest that MHL acts as a ZIKV NS5 RNA-dependent RNA polymerase (RdRp) inhibitor, supported by a structure-activity relationship (SAR) analysis showing the correlation between the inhibitory effect upon viral RNA synthesis and ZIKV infectivity. Furthermore, MHL was shown to bind ZIKV NS5 RdRp in vitro and predicted to interact with key residues at the active site of ZIKV NS5 RdRp by molecular docking analysis. Reference: Bioorg Chem. 2022 Nov;128:106024. https://pubmed.ncbi.nlm.nih.gov/35901544/

In vivo activity:

Mebhydrolin ameliorated blood glucose homeostasis in T2DM mice by both suppressing hepatic gluconeogenesis via FXR/miR-22-3p/PI3K/AKT/FoxO1 pathway and promoting glycogen synthesis through FXR/miR-22-3p/PI3K/AKT/GSK3β pathway. Structurally, residues L291, M332 and Y373 of FXR were required for Mebhydrolin binding to FXR-LBD, and Mebhydrolin induced H2 and H6 shifting of FXR potently affecting the regulation of the downstream target genes. Reference: Metabolism. 2021 Jun;119:154771. https://pubmed.ncbi.nlm.nih.gov/33831422/

	Solvent	mg/mL	mM
Solubility
	DMSO	6.8	8.06

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 841.05 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Zhou R, Li Q, Yang B, Quan Y, Liu Y, Liu M, Zhang Y, Shan G, Li Z, Wang J, Li Y, Cen S. Repurposing of the antihistamine mebhydrolin napadisylate for treatment of Zika virus infection. Bioorg Chem. 2022 Nov;128:106024. doi: 10.1016/j.bioorg.2022.106024. Epub 2022 Jul 22. PMID: 35901544. 2. Zhao T, Wang J, He A, Wang S, Chen Y, Lu J, Lv J, Li S, Wang J, Qian M, Li H, Shen X. Mebhydrolin ameliorates glucose homeostasis in type 2 diabetic mice by functioning as a selective FXR antagonist. Metabolism. 2021 Jun;119:154771. doi: 10.1016/j.metabol.2021.154771. Epub 2021 Apr 5. PMID: 33831422.

In vitro protocol:

Zhou R, Li Q, Yang B, Quan Y, Liu Y, Liu M, Zhang Y, Shan G, Li Z, Wang J, Li Y, Cen S. Repurposing of the antihistamine mebhydrolin napadisylate for treatment of Zika virus infection. Bioorg Chem. 2022 Nov;128:106024. doi: 10.1016/j.bioorg.2022.106024. Epub 2022 Jul 22. PMID: 35901544.

In vivo protocol:

Zhao T, Wang J, He A, Wang S, Chen Y, Lu J, Lv J, Li S, Wang J, Qian M, Li H, Shen X. Mebhydrolin ameliorates glucose homeostasis in type 2 diabetic mice by functioning as a selective FXR antagonist. Metabolism. 2021 Jun;119:154771. doi: 10.1016/j.metabol.2021.154771. Epub 2021 Apr 5. PMID: 33831422.

1: McEwen J, Strickland WJ. Mebhydrolin napadisylate. A possible cause of reversible agranulocytosis and neutropenia. Med J Aust. 1982 Nov 27;2(11):523-5. PMID: 6130466. 2: Edoute Y, Nagler A, Brenner B. [Agranulocytosis associated with mebhydrolin napadisylate (Incidal)]. Harefuah. 1984 Mar 1;106(5):208-9. Hebrew. PMID: 6724409. 3: Li Z, Ye CY, Zhao TY, Yang L. Model of genetic and environmental factors associated with type 2 diabetes mellitus in a Chinese Han population. BMC Public Health. 2020 Jun 29;20(1):1024. doi: 10.1186/s12889-020-09130-5. PMID: 32600448; PMCID: PMC7325035. 4: Stoop D, Vercammen L, Polyzos NP, de Vos M, Nekkebroeck J, Devroey P. Effect of ovarian stimulation and oocyte retrieval on reproductive outcome in oocyte donors. Fertil Steril. 2012 Jun;97(6):1328-30. doi: 10.1016/j.fertnstert.2012.03.012. Epub 2012 Mar 30. PMID: 22464081. 5: Bello AI, Quartey JN, Appiah LA. Screening for developmental delay among children attending a rural community welfare clinic in Ghana. BMC Pediatr. 2013 Aug 13;13:119. doi: 10.1186/1471-2431-13-119. PMID: 23937954; PMCID: PMC3751115. 6: Nakagawa H, Fujiwara N, Tateishi R, Arano T, Nakagomi R, Kondo M, Minami T, Sato M, Uchino K, Enooku K, Asaoka Y, Kondo Y, Shiina S, Yoshida H, Koike K. Impact of serum levels of interleukin-6 and adiponectin on all-cause, liver- related, and liver-unrelated mortality in chronic hepatitis C patients. J Gastroenterol Hepatol. 2015 Feb;30(2):379-88. doi: 10.1111/jgh.12719. PMID: 25168107. 7: Lee YC, Lin CH, Lin MS, Lin JW, Chang CH, Lai MS. Effects of selective serotonin reuptake inhibitors versus tricyclic antidepressants on cerebrovascular events: a nationwide population-based cohort study. J Clin Psychopharmacol. 2013 Dec;33(6):782-9. doi: 10.1097/JCP.0b013e31829c970e. PMID: 24091857. 8: Wu B, Wang HL, Cee VJ, Lanman BA, Nixey T, Pettus L, Reed AB, Wurz RP, Guerrero N, Sastri C, Winston J, Lipford JR, Lee MR, Mohr C, Andrews KL, Tasker AS. Discovery of 5-(1H-indol-5-yl)-1,3,4-thiadiazol-2-amines as potent PIM inhibitors. Bioorg Med Chem Lett. 2015 Feb 15;25(4):775-80. doi: 10.1016/j.bmcl.2014.12.091. Epub 2015 Jan 7. PMID: 25616902. 9: KHARKEVICH DA. K farmakologii diazolina [Pharmacology of diazoline]. Farmakol Toksikol. 1957 Nov-Dec;20(6):46-51. Russian. PMID: 13562138. 10: Verstraete E, Boelens J, De Coen K, Claeys G, Vogelaers D, Vanhaesebrouck P, Blot S. Healthcare-associated bloodstream infections in a neonatal intensive care unit over a 20-year period (1992-2011): trends in incidence, pathogens, and mortality. Infect Control Hosp Epidemiol. 2014 May;35(5):511-8. doi: 10.1086/675836. Epub 2014 Mar 17. PMID: 24709719.